225 related articles for article (PubMed ID: 20211437)
1. The application of phenotypic high-throughput screening techniques to cardiovascular research.
Etzion Y; Muslin AJ
Trends Cardiovasc Med; 2009 Aug; 19(6):207-12. PubMed ID: 20211437
[TBL] [Abstract][Full Text] [Related]
2. Organs-on-chip models for cardiovascular drug development.
Zimmermann WH
Cardiovasc Res; 2021 Nov; 117(12):e164-e165. PubMed ID: 34347045
[No Abstract] [Full Text] [Related]
3. Recent progress in the use of zebrafish for novel cardiac drug discovery.
Keßler M; Rottbauer W; Just S
Expert Opin Drug Discov; 2015; 10(11):1231-41. PubMed ID: 26294375
[TBL] [Abstract][Full Text] [Related]
4. Streamlining drug discovery assays for cardiovascular disease using zebrafish.
Pott A; Rottbauer W; Just S
Expert Opin Drug Discov; 2020 Jan; 15(1):27-37. PubMed ID: 31570020
[No Abstract] [Full Text] [Related]
5. Screening drugs for myocardial disease in vivo with zebrafish: an expert update.
Zhao Y; Zhang K; Sips P; MacRae CA
Expert Opin Drug Discov; 2019 Apr; 14(4):343-353. PubMed ID: 30836799
[TBL] [Abstract][Full Text] [Related]
6. Induced pluripotent stem cells in cardiovascular drug discovery.
Mercola M; Colas A; Willems E
Circ Res; 2013 Feb; 112(3):534-48. PubMed ID: 23371902
[TBL] [Abstract][Full Text] [Related]
7. The Future of Cardiovascular Therapeutics.
MacRae CA; Roden DM; Loscalzo J
Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
[No Abstract] [Full Text] [Related]
8. Cardiovascular pharmacology in the post-blockbuster era.
Brandes RP
Curr Opin Pharmacol; 2010 Apr; 10(2):109-10. PubMed ID: 20202904
[No Abstract] [Full Text] [Related]
9. Cardiovascular-Active Venom Toxins: An Overview.
Rebello Horta CC; Chatzaki M; Rezende BA; Magalhães Bde F; Duarte CG; Felicori LF; Ribeiro Oliveira-Mendes BB; do Carmo AO; Chávez-Olórtegui C; Kalapothakis E
Curr Med Chem; 2016; 23(6):603-22. PubMed ID: 26812904
[TBL] [Abstract][Full Text] [Related]
10. The importance of drug discovery for treatment of cardiovascular diseases.
Kennedy C
Future Med Chem; 2013 Mar; 5(4):355-7. PubMed ID: 23495678
[No Abstract] [Full Text] [Related]
11. Extracellular and Intracellular Cyclophilin A, Native and Post-Translationally Modified, Show Diverse and Specific Pathological Roles in Diseases.
Xue C; Sowden MP; Berk BC
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):986-993. PubMed ID: 29599134
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of neuregulin-1 in cardiovascular disease.
Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
[TBL] [Abstract][Full Text] [Related]
13. Leveraging human genetics to guide drug target discovery.
Stitziel NO; Kathiresan S
Trends Cardiovasc Med; 2017 Jul; 27(5):352-359. PubMed ID: 27686272
[TBL] [Abstract][Full Text] [Related]
14. Novel Beneficial Cardiovascular Effects of Natural Activators of Autophagy.
Frati G; Vecchione C; Sciarretta S
Circ Res; 2018 Sep; 123(8):947-949. PubMed ID: 30355035
[No Abstract] [Full Text] [Related]
15. Screening for chemical modulators for LRRK2.
Mortiboys H
Biochem Soc Trans; 2016 Dec; 44(6):1617-1623. PubMed ID: 27913670
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic high-throughput screening in atherosclerosis research: focus on macrophages.
Muslin AJ
J Cardiovasc Transl Res; 2010 Oct; 3(5):448-53. PubMed ID: 20625867
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology.
Salabei JK; Conklin DJ
Cardiovasc Toxicol; 2013 Sep; 13(3):220-9. PubMed ID: 23408289
[TBL] [Abstract][Full Text] [Related]
19. Curcumin and cardiovascular diseases: Focus on cellular targets and cascades.
Pourbagher-Shahri AM; Farkhondeh T; Ashrafizadeh M; Talebi M; Samargahndian S
Biomed Pharmacother; 2021 Apr; 136():111214. PubMed ID: 33450488
[TBL] [Abstract][Full Text] [Related]
20. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
Lizotte-Waniewski M; Brew K; Hennekens CH
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
